Widely-released "Internal" FDA report's post-market claim are flawed, says industry
This article was originally published in Clinica
Executive Summary
US industry officials are challenging the results of the FDA's recent high-profile study, which found that a significant percentage of post-market studies are never completed, writes Karen Riley at the Food and Drug Law Institute annual meeting.